$10.50
2.69% yesterday
Nasdaq, Aug 18, 10:00 pm CET
ISIN
US89357L1052
Symbol
RNAZ

TransCode Therapeutics Inc Stock price

$10.50
+0.56 5.63% 1M
-289.10 96.50% 6M
-83.86 88.87% YTD
-238.89 95.79% 1Y
-909,205.50 100.00% 3Y
-2,956,789.50 100.00% 5Y
-2,956,789.50 100.00% 10Y
-2,956,789.50 100.00% 20Y
Nasdaq, Closing price Mon, Aug 18 2025
-0.29 2.69%
ISIN
US89357L1052
Symbol
RNAZ
Industry

Key metrics

Basic
Market capitalization
$9.2m
Enterprise Value
$-2.4m
Net debt
positive
Cash
$11.6m
Shares outstanding
-
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
0.2
P/B
0.9
Financial Health
Equity Ratio
-27.7%
Return on Equity
831.5%
ROCE
-
ROIC
-
Debt/Equity
-
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-14.3m | -
EBIT
$-14.7m | $-12.2m
Net Income
$-24.6m | -
Free Cash Flow
$-14.4m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
17.8% | -
EBIT
17.6% | 21.8%
Net Income
-37.5% | -
Free Cash Flow
7.2%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-29.5
FCF per Share
-
Short interest
13.7%
Employees
7
Rev per Employee
$0.0
Show more

Is TransCode Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,018 stocks worldwide.

TransCode Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a TransCode Therapeutics Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a TransCode Therapeutics Inc forecast:

Buy
86%
Hold
14%

Financial data from TransCode Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 5 5
20% 20%
-
- Research and Development Expense 9.65 9.65
16% 16%
-
-14 -14
18% 18%
-
- Depreciation and Amortization 0.32 0.32
9% 9%
-
EBIT (Operating Income) EBIT -15 -15
18% 18%
-
Net Profit -25 -25
38% 38%
-

In millions USD.

Don't miss a Thing! We will send you all news about TransCode Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

TransCode Therapeutics Inc Stock News

Neutral
PRNewsWire
3 months ago
RNA pioneer and biotechnology innovator joins TransCode Therapeutics Science Advisory Board to advance RNA oncology Dr. Zamore co-founded Alnylam Pharmaceuticals in 2002, which developed and commercialized the first FDA-approved RNAi drug BOSTON , May 28, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), a clinical-stage oncology company developing RNA-targeted therapeutics for ...
Neutral
PRNewsWire
3 months ago
15 patients treated across four escalating dose levels of TTX-MC138 No significant safety or dose limiting toxicities reported 10 patients remain on study with no evidence of disease progression PD analysis at 24 hours post-dosing provides evidence of miR-10b target engagement BOSTON , May 8, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to...
Neutral
PRNewsWire
4 months ago
BOSTON , May 5, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that its Board of Directors has approved an effective time at 12:01 a.m. Eastern Standard Time May 15, 2025, for its 1-for-28 reverse stock split.
More TransCode Therapeutics Inc News

Company Profile

TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Boston, MA.

Head office United States
CEO Thomas Fitzgerald
Employees 7
Founded 2016
Website www.transcodetherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today